Xie Zhipeng

Dr. Xie Zhipeng

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JLJiaxiang Liang
Jiaxiang Liang
XZXie Zhipeng
Xie Zhipeng
SSSun Yingjie Sun
Sun Yingjie Sun
YTYuheng Tang
Yuheng Tang
GGGul Gul
Gul Gul
XZXuhong Zhou
Xuhong Zhou
This study systematically explored immune targets in gastric adenocarcinoma (GAC) suitable for mRNA vaccine development. Based on multi-omics data from public databases, we first screened a set of potential tumor-associated antigen genes. Subsequently, using ten machine learning algorithms, we constructed 101 prognostic models and, through optimization and comparison, selected the Random Survival Forest (RSF) method to establish a clinical prognostic model for GAC consisting of seven genes (TYMP, IFGN, ITGAX, GBP5, GBP4, STAT1, CD84). At both the genetic and protein levels, these genes were closely associated with the antigen presentation process, suggesting the potential functional role of this model in antigen presentation. Further analysis of the immune infiltration characteristics in GAC preliminarily revealed its possible immune evasion mechanisms. Building on this, we designed candidate mRNA vaccine templates for GAC using the mRNAdesigner platform. Additionally, this study investigated the potential roles of the above seven genes in GAC progression and screened small-molecule compounds targeting these genes. Molecular dynamics simulations (MD) were performed to verify the binding stability between these compounds and their corresponding proteins. This study comprehensively simulated the tumor microenvironment (TME) and antigen presentation process in GAC, evaluated the clinical translation potential of the neoantigen prognostic model and its predictive value for immunotherapy, and provided a preliminary design scheme for an mRNA vaccine against GAC. The findings offer new evidence for identifying immune therapy targets in GAC and are expected to advance the development of immunotherapy strategies for GAC.

Verified
Journal Article
Open access
PDF file
XZXie Zhipeng
Xie Zhipeng
SSSun Yingjie Sun
Sun Yingjie Sun
YTYuheng Tang
Yuheng Tang
QQQi Qi
Qi Qi
JLJiaxiang Liang
Jiaxiang Liang
XZXuhong Zhou
Xuhong Zhou
Prostate cancer (PCa) remains a major global health concern, with a subset of patients progressing to aggressive disease despite advances in diagnosis and treatment. Epithelial–mesenchymal transition (EMT) plays a pivotal role in tumor invasion, metastasis, and immune evasion; however, its cellular heterogeneity and clinical relevance in PCa remain incompletely understood. We analyzed single-cell transcriptomic data to characterize EMT dynamics in malignant epithelial cells. Malignant cells were identified based on aberrant copy number variation patterns, and EMT activity was quantified using AUCell. Gene expression profiling and gene set enrichment analysis identified key EMT-associated genes. By integrating bulk transcriptomic data with LASSO regression analysis, we identified five pivotal genes and constructed an EMT infiltration scoring model. The model demonstrated robust predictive performance in an external Gene Expression Omnibus validation cohort and effectively predicted early biochemical recurrence. Further analyses revealed significant associations between EMT scores, clinicopathological features, immune cell infiltration, genomic instability, and tumor immune dysfunction and exclusion scores. Pathway enrichment analysis highlighted distinct molecular characteristics between high- and low-score groups. Additionally, molecular docking using AutoDock identified potential targeted therapeutic agents for key EMT genes. Overall, this study systematically delineates EMT heterogeneity at the single-cell level and establishes a robust EMT infiltration model for prognostic prediction and therapeutic guidance in PCa, providing novel insights for precision risk stratification and individualized treatment strategies.